加载中
MediciNova, Inc. is a biopharmaceutical firm dedicated to discovering and advancing innovative small molecule therapies for severe illnesses where current treatments are insufficient within the United States. Its robust development pipeline features MN-166 (ibudilast), an oral agent with both anti-inflammatory and neuroprotective properties, currently being investigated for a range of neurological conditions. These include primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and various forms of substance dependence and addiction. The company's portfolio also comprises MN-221 (bedoradrine), a selective beta-2-adrenergic receptor agonist aimed at treating acute asthma attacks; MN-001 (tipelukast), an orally available small molecule designed for fibrotic disorders like nonalcoholic steatohepatitis and idiopathic pulmonary fibrosis; and MN-029 (denibulin), a tubulin binding agent intended for solid tumor oncology. MediciNova has established strategic partnerships with companies such as Kissei Pharmaceutical Co., Ltd., Kyorin Pharmaceutical Co., Ltd., Angiogene Pharmaceuticals Ltd., and Meiji Seika Kaisha Ltd. Established in 2000, the company's headquarters are situated in La Jolla, California.
收盘时
US$1.54
+US$0.02 · +1.32%
盘后
US$1.51
−US$0.03 · -1.95%
10月12日 16:54 ET
盘中时间采用ET。市场数据可能有所延迟。
MediciNova, Inc. is a biopharmaceutical firm dedicated to discovering and advancing innovative small molecule therapies for severe illnesses where current treatments are insufficient within the United States. Its robust development pipeline features MN-166 (ibudilast), an oral agent with both anti-inflammatory and neuroprotective properties, currently being investigated for a range of neurological conditions. These include primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and various forms of substance dependence and addiction. The company's portfolio also comprises MN-221 (bedoradrine), a selective beta-2-adrenergic receptor agonist aimed at treating acute asthma attacks; MN-001 (tipelukast), an orally available small molecule designed for fibrotic disorders like nonalcoholic steatohepatitis and idiopathic pulmonary fibrosis; and MN-029 (denibulin), a tubulin binding agent intended for solid tumor oncology. MediciNova has established strategic partnerships with companies such as Kissei Pharmaceutical Co., Ltd., Kyorin Pharmaceutical Co., Ltd., Angiogene Pharmaceuticals Ltd., and Meiji Seika Kaisha Ltd. Established in 2000, the company's headquarters are situated in La Jolla, California.
日内区间
当前US$1.54
52周区间
当前US$1.54
盘中时间采用ET。市场数据可能有所延迟。
GoAI 评分
卖出
估值
26
偏贵
情绪
56
多空交织
风险
51
风险偏高
动量
40
动能减弱
完整 GoAI 研究
继续查看更深入的依据、催化因素和风险。
MediciNova, Inc. is a biopharmaceutical firm dedicated to discovering and advancing innovative small molecule therapies for severe illnesses where current treatments are insufficient within the United States. Its robust development pipeline features MN-166 (ibudilast), an oral agent with both anti-inflammatory and neuroprotective properties, currently being investigated for a range of neurological conditions. These include primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and various forms of substance dependence and addiction. The company's portfolio also comprises MN-221 (bedoradrine), a selective beta-2-adrenergic receptor agonist aimed at treating acute asthma attacks; MN-001 (tipelukast), an orally available small molecule designed for fibrotic disorders like nonalcoholic steatohepatitis and idiopathic pulmonary fibrosis; and MN-029 (denibulin), a tubulin binding agent intended for solid tumor oncology. MediciNova has established strategic partnerships with companies such as Kissei Pharmaceutical Co., Ltd., Kyorin Pharmaceutical Co., Ltd., Angiogene Pharmaceuticals Ltd., and Meiji Seika Kaisha Ltd. Established in 2000, the company's headquarters are situated in La Jolla, California.
日内区间
当前US$1.54
52周区间
当前US$1.54
盈利能力占已公布营收的百分比。
营收
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 营收 | 40.97万 USD | — | 100万 USD | — | 403.75万 USD |
| 销货成本 | 37.86万 USD | — | — | — | — |
| 毛利 | 3.11万 USD | — | 100万 USD | — | 403.75万 USD |
| 研究与开发 | 715.53万 USD | 719.51万 USD | 565.83万 USD | 914.34万 USD | 810万 USD |
| 销售、一般及管理费用 | 615.92万 USD | 548.06万 USD | 524.24万 USD | 548.49万 USD | 571.53万 USD |
| 营业费用 | 1331.41万 USD | 1267.53万 USD | 1090.03万 USD | 1462.86万 USD | 1425.33万 USD |
| 利息收入 | 130.38万 USD | 167.08万 USD | 183.47万 USD | 80.97万 USD | 14.36万 USD |
| 折旧和摊销 | 2.01万 USD | 2.11万 USD | 2.03万 USD | 1.77万 USD | 2.61万 USD |
| 营业利润 | −1328.3万 USD | −1267.53万 USD | −990.03万 USD | −1462.86万 USD | −1021.58万 USD |
| 净利润 | −1199.8万 USD | −1104.95万 USD | −857.15万 USD | −1406.91万 USD | −1013.43万 USD |
公司数据更新于 2026年10月12日。
近期已公布业绩
近期已公布业绩
第三方分析师预期可能变化，并非 GoAI 建议。
平均目标
US$6.00
上涨空间 289.61%报告持有此股票敞口的交易所交易基金。
AI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
